A carregar...
Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial
Methods to deepen clinical responses to ibrutinib are needed to improve outcomes for patients with chronic lymphocytic leukemia (CLL). This study aimed to determine the safety and efficacy of combining a janus kinase (JAK)‐inhibitor with ibrutinib because JAK‐mediated cytokine‐signals support CLL ce...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488147/ https://ncbi.nlm.nih.gov/pubmed/30843659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2042 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|